Drug Profile
S 0139
Alternative Names: 737004; SB 737004Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Shionogi
- Developer Shionogi; Shionogi-GlaxoSmithKline Pharmaceuticals
- Class Neuroprotectants
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cerebrovascular disorders; Stroke
Most Recent Events
- 25 May 2010 Discontinued - Phase-I for Cerebrovascular disorders in Europe (Injection)
- 25 May 2010 Discontinued - Phase-I for Stroke in Europe (Injection)
- 25 May 2010 Discontinued - Phase-II for Cerebrovascular disorders in Japan (Injection)